Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Seagen patents

Patents where

Current Assignee

Name

Seagen

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7498298 Monomethylvaline compounds capable of conjugation to ligands	Patent 7498298 was granted and assigned to Seagen on March, 2009 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7498298	March 3, 2009
‌ US Patent 7754681 Heterocyclic self-immolative linkers and conjugates	Patent 7754681 was granted and assigned to Seagen on July, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7754681	July 13, 2010
‌ US Patent 7090843 Recombinant anti-CD30 antibodies and uses thereof	Patent 7090843 was granted and assigned to Seagen on August, 2006 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7090843	August 15, 2006
‌ US Patent 10464997 Selective reduction of proteins	Patent 10464997 was granted and assigned to Seagen on November, 2019 by the United States Patent and Trademark Office.	Seagen	Seagen	United States Patent and Trademark Office	10464997	November 5, 2019
‌ US Patent 7989434 Heterocyclic self-immolative linkers and conjugates	Patent 7989434 was granted and assigned to Seagen on August, 2011 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7989434	August 2, 2011
‌ US Patent 6884869 Pentapeptide compounds and uses related thereto	Patent 6884869 was granted and assigned to Seagen on April, 2005 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	6884869	April 26, 2005
‌ US Patent 7659241 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease	Patent 7659241 was granted and assigned to Seagen on February, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7659241	February 9, 2010
‌ US Patent 7553816 None	Patent 7553816 was granted and assigned to Seagen on June, 2009 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7553816	June 30, 2009
‌ US Patent 7091186 None	Patent 7091186 was granted and assigned to Seagen on August, 2006 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7091186	August 15, 2006
‌ US Patent 11351269 Anti-NTB-A antibodies and related compositions and methods	Patent 11351269 was granted and assigned to Seagen on June, 2022 by the United States Patent and Trademark Office.	Seagen	Seagen	United States Patent and Trademark Office	11351269	June 7, 2022
‌ US Patent 7964566 Monomethylvaline compounds capable of conjugation to ligands	Patent 7964566 was granted and assigned to Seagen on June, 2011 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7964566	June 21, 2011
‌ US Patent 7829531 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease	Patent 7829531 was granted and assigned to Seagen on November, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7829531	November 9, 2010
‌ US Patent 8067546 Humanized anti-CD70 binding agents and uses thereof	Patent 8067546 was granted and assigned to Seagen on November, 2011 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	8067546	November 29, 2011
‌ US Patent 7837980 Partially loaded antibodies and methods of their conjugation	Patent 7837980 was granted and assigned to Seagen on November, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7837980	November 23, 2010
‌ US Patent 8703714 Monomethylvaline compounds capable of conjugation to ligands	Patent 8703714 was granted and assigned to Seagen on April, 2014 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	8703714	April 22, 2014
‌ US Patent 7662387 Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders	Patent 7662387 was granted and assigned to Seagen on February, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7662387	February 16, 2010
‌ US Patent 7491390 Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders	Patent 7491390 was granted and assigned to Seagen on February, 2009 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7491390	February 17, 2009
‌ US Patent 8455622 Variant target binding agents and uses thereof	Patent 8455622 was granted and assigned to Seagen on June, 2013 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	8455622	June 4, 2013
‌ US Patent 7745394 Monomethylvaline compounds capable of conjugation to ligands	Patent 7745394 was granted and assigned to Seagen on June, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7745394	June 29, 2010
‌ US Patent 7750116 Antibody drug conjugate metabolites	Patent 7750116 was granted and assigned to Seagen on July, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7750116	July 6, 2010
‌ US Patent 8663642 Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disorders	Patent 8663642 was granted and assigned to Seagen on March, 2014 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	8663642	March 4, 2014
‌ US Patent 9345785 Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugates	Patent 9345785 was granted and assigned to Seagen on May, 2016 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	9345785	May 24, 2016
‌ US Patent 7641903 Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders	Patent 7641903 was granted and assigned to Seagen on January, 2010 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7641903	January 5, 2010
‌ US Patent 7098308 Pentapeptide compounds and uses related thereto	Patent 7098308 was granted and assigned to Seagen on August, 2006 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7098308	August 29, 2006
‌ US Patent 7256257 Pentapeptide compounds and uses related thereto	Patent 7256257 was granted and assigned to Seagen on August, 2007 by the United States Patent and Trademark Office.		Seagen	United States Patent and Trademark Office	7256257	August 14, 2007

...

Results per page:

120 results

0 selected

120 results

0 selected